Shopping Cart 0
Cart Subtotal
USD 0

Global Biologics Market Research Report: by Product (Monoclonal Antibody, Interleukins, Vaccines, Growth Factors, Gene Therapy, Others), by Disease Indication (Rheumatoid Arthritis, Psoriasis/Psoriatic Arthritis, Cancer, Diabetes, Others), by Manufacturing (In-house, Sourced), and Region - Forecast to 2023

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 4450

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6250
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Global Biologics Market Research Report: by Product (Monoclonal Antibody, Interleukins, Vaccines, Growth Factors, Gene Therapy, Others), by Disease Indication (Rheumatoid Arthritis, Psoriasis/Psoriatic Arthritis, Cancer, Diabetes, Others), by Manufacturing (In-house, Sourced), and Region-Forecast to 2023

Market analysis

Biologics are those products that are derived from animals, humans and microorganisms through biotechnology. Medications delivered utilizing biologics are being utilized to treat a variety of interminable ailments. Continuous development in the pharmaceutical segment is probably going to support the interest for biologics. The Biologics Market is driven by the prominence of chronic diseases and the all-inclusive medicinal budget of the countries. Enhancements seen in the healthcare infrastructure combined with changes by different nations is probably going to be favorable for the global biologics market growth during the forecast period. However, with the advent of the biosimilars, the biologics market could experience a challenge. The global Biologics Market is growing at a CAGR of 6.95% and is projected to reach the value of USD 285,520.4 million by the end of the forecast period (2018-2023).

Market segmentation

Based on its product, the global Biologics Market is segmented into interleukins, monoclonal antibody, vaccines, gene therapy, growth factors, and others. By disease indication, the market is bifurcated into cancer, rheumatoid arthritis, diabetes, psoriasis/psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, Crohn's disease, cardiovascular diseases, juvenile idiopathic arthropathy, and others. On the basis of its manufacturing, the market is classified, mainly in-house and outsourced.

Regional analysis

Geographically, the global Biologics Market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

The major players profiled in the global biologics market report include companies like Novartis AG (Switzerland), F. Hoffman-La Roche AG (Switzerland), AbbVie, Inc. (U.S.), Pfizer Inc. (U.S.), AstraZeneca (U.K.), Bayer AG (Germany), Amgen (U.S.), GlaxoSmithKline Plc (U.K.), Sanofi (France), Eli Lilly and Company (U.S.), and others.

READ MORE

Table Of Content

Scope

Table of Contents:

1 Report Prologue

2 Market Introduction

2.1 Introduction

2.2 Scope of the Study

2.3 Assumptions & Limitations

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4 Market Dynamics

4.1 Introduction

4.2 Drivers

4.2.1 Increasing Healthcare Expenditure

4.2.2 Advancements in Biologics

4.2.3 Rising Prevalence of Chronic and Acute Diseases

4.3 Restraints

4.3.1 Emergence of Biosimilars

4.3.2 Adverse Effects of Biologic Drugs

4.4 Opportunities

4.4.1 Strong Pipeline for Biologic Drugs

5 Market Factor Analysis

5.1 Value/Supply Chain Analysis

5.1.1 Research & Development

5.1.2 Raw Material

5.1.3 Manufacturer

5.1.4 Distributor

5.1.5 Customer

5.1.6 Consumer

5.2 Porter's Five Force Analysis

5.2.1 Threat from a New Entrant

5.2.2 Bargaining Power of Buyer

5.2.3 Bargaining Power of Supplier

5.2.4 Threat from Substitute

5.2.5 Rivalry

5.3 Investment Opportunity Analysis

5.3.1 Investment Risks

5.3.2 Market Outlook

5.4 Pricing Analysis

6 Global Biologics Market, by Product

6.1 Overview

6.2 Monoclonal Antibody

6.2.1 Humanized

6.2.2 Human

6.2.3 Chimeric

6.2.4 Murine

6.3 Interleukins

6.4 Vaccines

6.5 Growth Factors

6.6 Gene Therapy

7 Global Biologics Market, by Disease Indication

7.1 Overview

7.2 Cancer

7.3 Rheumatoid Arthritis

7.4 Psoriasis/ Psoriatic Arthritis

7.5 Diabetes

7.6 Ankylosing Spondylitis

7.7 Ulcerative Colitis

7.8 Crohn's Disease

7.9 Juvenile Idiopathic Arthropathy

7.1 Cardiovascular Diseases

8 Global Biologics Market, by Manufacturing

8.1 Overview

8.2 In-house

8.3 Outsourced

?

9 Global Biologics Market, by Region

9.1 Overview

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 UK

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

10 Competitive Landscape

10.1 Company Market Share Analysis

10.2 Competitive Scenario

11 Company Profiles

11.1 AbbVie, Inc.

11.1.1 Company Overview

11.1.2 Financial Overview

11.1.3 Products/Services Offering

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.1.6 Key Strategy

11.2 Pfizer Inc.

11.2.1 Company Overview

11.2.2 Financial Overview

11.2.3 Products/Services Offering

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.2.6 Key Strategy

11.3 AstraZeneca

11.3.1 Company Overview

11.3.2 Financial Overview

11.3.3 Products/Services Offering

11.3.4 Key Developments

11.3.5 SWOT Analysis

11.3.6 Key Strategy

11.4 Novartis AG

11.4.1 Company Overview

11.4.2 Financial Overview

11.4.3 Products Offering

11.4.4 Key Developments

11.4.5 SWOT Analysis

11.4.6 Key Strategy

11.5 F. Hoffmann-La Roche AG

11.5.1 Company Overview

11.5.2 Financial Overview

11.5.3 Products Offering

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.5.6 Key Strategy

11.6 Bayer AG

11.6.1 Company Overview

11.6.2 Financial Overview

11.6.3 Products Offering

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.6.6 Key Strategy

11.7 Amgen

11.7.1 Company Overview

11.7.2 Financial Overview

11.7.3 Products Offering

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.7.6 Key Strategy

11.8 Sanofi

11.8.1 Company Overview

11.8.2 Financial Overview

11.8.3 Products Offering

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.8.6 Key Strategy

11.9 Eli Lilly and Company

11.9.1 Company Overview

11.9.2 Financial Overview

11.9.3 Products Offering

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.9.6 Key Strategy

11.1 GlaxoSmithKline Plc (GSK)

11.10.1 Company Overview

11.10.2 Financial Overview

11.10.3 Products Offering

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.10.6 Key Strategy

12 Appendix

12.1 Discussion Blue Print


List Of Figure

List of Figures:

FIGURE 1 MARKET STRUCTURE

FIGURE 2 RESEARCH PROCESS

FIGURE 3 TOP DOWN & BOTTOM-UP APPROACH

FIGURE 4 MARKET DYNAMICS: GLOBAL BIOLOGICS MARKET

FIGURE 5 VALUE CHAIN: GLOBAL BIOLOGICS MARKET

FIGURE 7 GLOBAL BIOLOGICS MARKET BY PRODUCT, 2017 & 2023 (USD MILLION)

FIGURE 8 GLOBAL BIOLOGICS MARKET BY DISEASE INDICATION, 2017 & 2023 (USD MILLION)

FIGURE 9 GLOBAL BIOLOGICS MARKET BY MANUFACTURING, 2017 & 2023 (USD MILLION)

FIGURE 10 GLOBAL BIOLOGICS MARKET BY REGION, 2017 & 2023 (USD MILLION)

FIGURE 11 AMERICAS BIOLOGICS MARKET BY REGION, 2017 (%)

FIGURE 12 NORTH AMERICA BIOLOGICS MARKET SHARE BY COUNTRY, 2017 (%)

FIGURE 13 EUROPE BIOLOGICS MARKET BY REGION, 2017 (%)

FIGURE 14 WESTERN EUROPE BIOLOGICS MARKET BY COUNTRY, 2017 (%)

FIGURE 15 ASIA-PACIFIC BIOLOGICS MARKET BY REGION, 2017 (%)

FIGURE 16 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY REGION, 2017 (%)

FIGURE 17 GLOBAL BIOLOGICS MARKET, MARKET SHARE ANALYSIS 2017 (%)

FIGURE 18 GLOBAL BIOLOGICS MARKET COMPETITIVE LANDSCAPE (%)


List Of Table

List of Tables:

TABLE 1 GLOBAL BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 2 GLOBAL BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 3 GLOBAL BIOLOGICS MARKET FOR INTERLEUKINS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 4 GLOBAL BIOLOGICS MARKET FOR HUMAN BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 5 GLOBAL BIOLOGICS MARKET FOR CHIMERIC BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 6 GLOBAL BIOLOGICS MARKET FOR MURINE BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 7 GLOBAL BIOLOGICS MARKET FOR INTERLEUKINS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 8 GLOBAL BIOLOGICS MARKET FOR VACCINES BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 9 GLOBAL BIOLOGICS MARKET FOR GROWTH FACTORS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 10 GLOBAL BIOLOGICS MARKET FOR GENE THERAPY BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 11 GLOBAL BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 12 GLOBAL BIOLOGICS MARKET FOR CANCER BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 13 GLOBAL BIOLOGICS MARKET FOR RHEUMATOID ARTHRITIS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 14 GLOBAL BIOLOGICS MARKET FOR PSORIASIS/ PSORIATIC ARTHRITIS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 15 GLOBAL BIOLOGICS MARKET FOR DIABETES BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 16 GLOBAL BIOLOGICS MARKET FOR ANKYLOSING SPONDYLITIS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 17 GLOBAL BIOLOGICS MARKET FOR ULCERATIVE COLITIS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 18 GLOBAL BIOLOGICS MARKET FOR CROHN'S DISEASE BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 19 GLOBAL BIOLOGICS MARKET FOR JUVENILE IDIOPATHIC ARTHROPATHY BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 20 GLOBAL BIOLOGICS MARKET FOR CARDIOVASCULAR DISEASES BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 21 GLOBAL BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 22 GLOBAL BIOLOGICS MARKET FOR IN-HOUSE BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 23 GLOBAL BIOLOGICS MARKET FOR OUTSOURCED BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 24 GLOBAL BIOLOGICS MARKET BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 25 AMERICAS BIOLOGICS MARKET BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 26 AMERICAS BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 27 AMERICAS BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 28 AMERICAS BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 29 AMERICAS BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 30 NORTH AMERICA BIOLOGICS MARKET BY COUNTRY, 2015 TO 2023 (USD MILLION)

TABLE 31 NORTH AMERICA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 32 NORTH AMERICA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 33 NORTH AMERICA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 34 NORTH AMERICA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 35 US BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 36 US BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 37 US BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 38 US BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 39 CANADA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 40 CANADA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 41 CANADA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 42 CANADA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 43 SOUTH AMERICA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 44 SOUTH AMERICA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 45 SOUTH AMERICA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 46 SOUTH AMERICA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 47 EUROPE BIOLOGICS MARKET BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 48 EUROPE BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 49 EUROPE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 50 EUROPE BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 51 EUROPE BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 52 WESTERN EUROPE BIOLOGICS MARKET BY COUNTRY, 2015 TO 2023 (USD MILLION)

TABLE 53 WESTERN EUROPE BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 54 WESTERN EUROPE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 55 WESTERN EUROPE BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 56 WESTERN EUROPE BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 57 GERMANY BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 58 GERMANY BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 59 GERMANY BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 60 GERMANY BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 61 FRANCE BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 62 FRANCE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 63 FRANCE BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 64 FRANCE BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 65 UK BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 66 UK BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 67 UK BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 68 UK BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 69 ITALY BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 70 ITALY BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 71 ITALY BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 72 ITALY BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 73 SPAIN BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 74 SPAIN BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 75 SPAIN BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 76 SPAIN BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 77 REST OF WESTERN EUROPE BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 78 REST OF WESTERN EUROPE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 79 REST OF WESTERN EUROPE BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 80 REST OF WESTERN EUROPE BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 81 EASTERN EUROPE BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 82 EASTERN EUROPE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 83 EASTERN EUROPE BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 84 EASTERN EUROPE BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 85 ASIA-PACIFIC BIOLOGICS MARKET BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 86 ASIA-PACIFIC BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 87 ASIA-PACIFIC BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 88 ASIA-PACIFIC BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 89 ASIA-PACIFIC BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 90 JAPAN BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 91 JAPAN BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 92 JAPAN BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 93 JAPAN BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 94 CHINA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 95 CHINA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 96 CHINA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 97 CHINA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 98 INDIA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 99 INDIA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 100 INDIA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 101 INDIA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 102 AUSTRALIA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 103 AUSTRALIA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 104 AUSTRALIA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 105 AUSTRALIA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 106 SOUTH KOREA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 107 SOUTH KOREA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 108 SOUTH KOREA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 109 SOUTH KOREA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 110 REST OF ASIA-PACIFIC BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 111 REST OF ASIA-PACIFIC BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 112 REST OF ASIA-PACIFIC BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 113 REST OF ASIA-PACIFIC BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 114 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 115 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 116 MIDDLE EAST & AFRICA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 117 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 118 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 119 MIDDLE EAST BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 120 MIDDLE EAST BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 121 MIDDLE EAST BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 122 MIDDLE EAST BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 123 AFRICA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 124 AFRICA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 125 AFRICA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 126 AFRICA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

Licence Rights

"Single User License: OnIine PDF View Only
Enterprise-user License : Print & download option is available."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Novartis AG (Switzerland), F. Hoffman-La Roche AG (Switzerland), AbbVie, Inc. (U.S.), Pfizer Inc. (U.S.), AstraZeneca (U.K.), Bayer AG (Germany), Amgen (U.S.), GlaxoSmithKline Plc (U.K.), Sanofi (France), Eli Lilly and Company (U.S.)

Global Biologics Market Research Report: by Product (Monoclonal Antibody, Interleukins, Vaccines, Growth Factors, Gene Therapy, Others), by Disease Indication (Rheumatoid Arthritis, Psoriasis/Psoriatic Arthritis, Cancer, Diabetes, Others), by Manufacturing (In-house, Sourced), and Region-Forecast to 2023

Market analysis

Biologics are those products that are derived from animals, humans and microorganisms through biotechnology. Medications delivered utilizing biologics are being utilized to treat a variety of interminable ailments. Continuous development in the pharmaceutical segment is probably going to support the interest for biologics. The Biologics Market is driven by the prominence of chronic diseases and the all-inclusive medicinal budget of the countries. Enhancements seen in the healthcare infrastructure combined with changes by different nations is probably going to be favorable for the global biologics market growth during the forecast period. However, with the advent of the biosimilars, the biologics market could experience a challenge. The global Biologics Market is growing at a CAGR of 6.95% and is projected to reach the value of USD 285,520.4 million by the end of the forecast period (2018-2023).

Market segmentation

Based on its product, the global Biologics Market is segmented into interleukins, monoclonal antibody, vaccines, gene therapy, growth factors, and others. By disease indication, the market is bifurcated into cancer, rheumatoid arthritis, diabetes, psoriasis/psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, Crohn's disease, cardiovascular diseases, juvenile idiopathic arthropathy, and others. On the basis of its manufacturing, the market is classified, mainly in-house and outsourced.

Regional analysis

Geographically, the global Biologics Market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

The major players profiled in the global biologics market report include companies like Novartis AG (Switzerland), F. Hoffman-La Roche AG (Switzerland), AbbVie, Inc. (U.S.), Pfizer Inc. (U.S.), AstraZeneca (U.K.), Bayer AG (Germany), Amgen (U.S.), GlaxoSmithKline Plc (U.K.), Sanofi (France), Eli Lilly and Company (U.S.), and others.

READ MORE

Scope

Table of Contents:

1 Report Prologue

2 Market Introduction

2.1 Introduction

2.2 Scope of the Study

2.3 Assumptions & Limitations

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4 Market Dynamics

4.1 Introduction

4.2 Drivers

4.2.1 Increasing Healthcare Expenditure

4.2.2 Advancements in Biologics

4.2.3 Rising Prevalence of Chronic and Acute Diseases

4.3 Restraints

4.3.1 Emergence of Biosimilars

4.3.2 Adverse Effects of Biologic Drugs

4.4 Opportunities

4.4.1 Strong Pipeline for Biologic Drugs

5 Market Factor Analysis

5.1 Value/Supply Chain Analysis

5.1.1 Research & Development

5.1.2 Raw Material

5.1.3 Manufacturer

5.1.4 Distributor

5.1.5 Customer

5.1.6 Consumer

5.2 Porter's Five Force Analysis

5.2.1 Threat from a New Entrant

5.2.2 Bargaining Power of Buyer

5.2.3 Bargaining Power of Supplier

5.2.4 Threat from Substitute

5.2.5 Rivalry

5.3 Investment Opportunity Analysis

5.3.1 Investment Risks

5.3.2 Market Outlook

5.4 Pricing Analysis

6 Global Biologics Market, by Product

6.1 Overview

6.2 Monoclonal Antibody

6.2.1 Humanized

6.2.2 Human

6.2.3 Chimeric

6.2.4 Murine

6.3 Interleukins

6.4 Vaccines

6.5 Growth Factors

6.6 Gene Therapy

7 Global Biologics Market, by Disease Indication

7.1 Overview

7.2 Cancer

7.3 Rheumatoid Arthritis

7.4 Psoriasis/ Psoriatic Arthritis

7.5 Diabetes

7.6 Ankylosing Spondylitis

7.7 Ulcerative Colitis

7.8 Crohn's Disease

7.9 Juvenile Idiopathic Arthropathy

7.1 Cardiovascular Diseases

8 Global Biologics Market, by Manufacturing

8.1 Overview

8.2 In-house

8.3 Outsourced

?

9 Global Biologics Market, by Region

9.1 Overview

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 UK

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

10 Competitive Landscape

10.1 Company Market Share Analysis

10.2 Competitive Scenario

11 Company Profiles

11.1 AbbVie, Inc.

11.1.1 Company Overview

11.1.2 Financial Overview

11.1.3 Products/Services Offering

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.1.6 Key Strategy

11.2 Pfizer Inc.

11.2.1 Company Overview

11.2.2 Financial Overview

11.2.3 Products/Services Offering

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.2.6 Key Strategy

11.3 AstraZeneca

11.3.1 Company Overview

11.3.2 Financial Overview

11.3.3 Products/Services Offering

11.3.4 Key Developments

11.3.5 SWOT Analysis

11.3.6 Key Strategy

11.4 Novartis AG

11.4.1 Company Overview

11.4.2 Financial Overview

11.4.3 Products Offering

11.4.4 Key Developments

11.4.5 SWOT Analysis

11.4.6 Key Strategy

11.5 F. Hoffmann-La Roche AG

11.5.1 Company Overview

11.5.2 Financial Overview

11.5.3 Products Offering

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.5.6 Key Strategy

11.6 Bayer AG

11.6.1 Company Overview

11.6.2 Financial Overview

11.6.3 Products Offering

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.6.6 Key Strategy

11.7 Amgen

11.7.1 Company Overview

11.7.2 Financial Overview

11.7.3 Products Offering

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.7.6 Key Strategy

11.8 Sanofi

11.8.1 Company Overview

11.8.2 Financial Overview

11.8.3 Products Offering

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.8.6 Key Strategy

11.9 Eli Lilly and Company

11.9.1 Company Overview

11.9.2 Financial Overview

11.9.3 Products Offering

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.9.6 Key Strategy

11.1 GlaxoSmithKline Plc (GSK)

11.10.1 Company Overview

11.10.2 Financial Overview

11.10.3 Products Offering

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.10.6 Key Strategy

12 Appendix

12.1 Discussion Blue Print


List Of Figure

List of Figures:

FIGURE 1 MARKET STRUCTURE

FIGURE 2 RESEARCH PROCESS

FIGURE 3 TOP DOWN & BOTTOM-UP APPROACH

FIGURE 4 MARKET DYNAMICS: GLOBAL BIOLOGICS MARKET

FIGURE 5 VALUE CHAIN: GLOBAL BIOLOGICS MARKET

FIGURE 7 GLOBAL BIOLOGICS MARKET BY PRODUCT, 2017 & 2023 (USD MILLION)

FIGURE 8 GLOBAL BIOLOGICS MARKET BY DISEASE INDICATION, 2017 & 2023 (USD MILLION)

FIGURE 9 GLOBAL BIOLOGICS MARKET BY MANUFACTURING, 2017 & 2023 (USD MILLION)

FIGURE 10 GLOBAL BIOLOGICS MARKET BY REGION, 2017 & 2023 (USD MILLION)

FIGURE 11 AMERICAS BIOLOGICS MARKET BY REGION, 2017 (%)

FIGURE 12 NORTH AMERICA BIOLOGICS MARKET SHARE BY COUNTRY, 2017 (%)

FIGURE 13 EUROPE BIOLOGICS MARKET BY REGION, 2017 (%)

FIGURE 14 WESTERN EUROPE BIOLOGICS MARKET BY COUNTRY, 2017 (%)

FIGURE 15 ASIA-PACIFIC BIOLOGICS MARKET BY REGION, 2017 (%)

FIGURE 16 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY REGION, 2017 (%)

FIGURE 17 GLOBAL BIOLOGICS MARKET, MARKET SHARE ANALYSIS 2017 (%)

FIGURE 18 GLOBAL BIOLOGICS MARKET COMPETITIVE LANDSCAPE (%)


List Of Table

List of Tables:

TABLE 1 GLOBAL BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 2 GLOBAL BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 3 GLOBAL BIOLOGICS MARKET FOR INTERLEUKINS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 4 GLOBAL BIOLOGICS MARKET FOR HUMAN BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 5 GLOBAL BIOLOGICS MARKET FOR CHIMERIC BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 6 GLOBAL BIOLOGICS MARKET FOR MURINE BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 7 GLOBAL BIOLOGICS MARKET FOR INTERLEUKINS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 8 GLOBAL BIOLOGICS MARKET FOR VACCINES BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 9 GLOBAL BIOLOGICS MARKET FOR GROWTH FACTORS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 10 GLOBAL BIOLOGICS MARKET FOR GENE THERAPY BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 11 GLOBAL BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 12 GLOBAL BIOLOGICS MARKET FOR CANCER BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 13 GLOBAL BIOLOGICS MARKET FOR RHEUMATOID ARTHRITIS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 14 GLOBAL BIOLOGICS MARKET FOR PSORIASIS/ PSORIATIC ARTHRITIS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 15 GLOBAL BIOLOGICS MARKET FOR DIABETES BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 16 GLOBAL BIOLOGICS MARKET FOR ANKYLOSING SPONDYLITIS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 17 GLOBAL BIOLOGICS MARKET FOR ULCERATIVE COLITIS BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 18 GLOBAL BIOLOGICS MARKET FOR CROHN'S DISEASE BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 19 GLOBAL BIOLOGICS MARKET FOR JUVENILE IDIOPATHIC ARTHROPATHY BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 20 GLOBAL BIOLOGICS MARKET FOR CARDIOVASCULAR DISEASES BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 21 GLOBAL BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 22 GLOBAL BIOLOGICS MARKET FOR IN-HOUSE BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 23 GLOBAL BIOLOGICS MARKET FOR OUTSOURCED BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 24 GLOBAL BIOLOGICS MARKET BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 25 AMERICAS BIOLOGICS MARKET BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 26 AMERICAS BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 27 AMERICAS BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 28 AMERICAS BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 29 AMERICAS BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 30 NORTH AMERICA BIOLOGICS MARKET BY COUNTRY, 2015 TO 2023 (USD MILLION)

TABLE 31 NORTH AMERICA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 32 NORTH AMERICA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 33 NORTH AMERICA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 34 NORTH AMERICA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 35 US BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 36 US BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 37 US BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 38 US BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 39 CANADA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 40 CANADA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 41 CANADA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 42 CANADA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 43 SOUTH AMERICA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 44 SOUTH AMERICA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 45 SOUTH AMERICA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 46 SOUTH AMERICA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 47 EUROPE BIOLOGICS MARKET BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 48 EUROPE BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 49 EUROPE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 50 EUROPE BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 51 EUROPE BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 52 WESTERN EUROPE BIOLOGICS MARKET BY COUNTRY, 2015 TO 2023 (USD MILLION)

TABLE 53 WESTERN EUROPE BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 54 WESTERN EUROPE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 55 WESTERN EUROPE BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 56 WESTERN EUROPE BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 57 GERMANY BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 58 GERMANY BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 59 GERMANY BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 60 GERMANY BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 61 FRANCE BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 62 FRANCE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 63 FRANCE BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 64 FRANCE BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 65 UK BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 66 UK BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 67 UK BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 68 UK BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 69 ITALY BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 70 ITALY BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 71 ITALY BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 72 ITALY BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 73 SPAIN BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 74 SPAIN BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 75 SPAIN BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 76 SPAIN BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 77 REST OF WESTERN EUROPE BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 78 REST OF WESTERN EUROPE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 79 REST OF WESTERN EUROPE BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 80 REST OF WESTERN EUROPE BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 81 EASTERN EUROPE BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 82 EASTERN EUROPE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 83 EASTERN EUROPE BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 84 EASTERN EUROPE BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 85 ASIA-PACIFIC BIOLOGICS MARKET BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 86 ASIA-PACIFIC BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 87 ASIA-PACIFIC BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 88 ASIA-PACIFIC BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 89 ASIA-PACIFIC BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 90 JAPAN BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 91 JAPAN BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 92 JAPAN BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 93 JAPAN BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 94 CHINA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 95 CHINA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 96 CHINA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 97 CHINA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 98 INDIA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 99 INDIA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 100 INDIA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 101 INDIA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 102 AUSTRALIA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 103 AUSTRALIA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 104 AUSTRALIA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 105 AUSTRALIA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 106 SOUTH KOREA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 107 SOUTH KOREA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 108 SOUTH KOREA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 109 SOUTH KOREA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 110 REST OF ASIA-PACIFIC BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 111 REST OF ASIA-PACIFIC BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 112 REST OF ASIA-PACIFIC BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 113 REST OF ASIA-PACIFIC BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 114 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY REGION, 2015 TO 2023 (USD MILLION)

TABLE 115 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 116 MIDDLE EAST & AFRICA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 117 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 118 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 119 MIDDLE EAST BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 120 MIDDLE EAST BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 121 MIDDLE EAST BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 122 MIDDLE EAST BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

TABLE 123 AFRICA BIOLOGICS MARKET BY PRODUCT, 2015 TO 2023 (USD MILLION)

TABLE 124 AFRICA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2015 TO 2023 (USD MILLION)

TABLE 125 AFRICA BIOLOGICS MARKET BY DISEASE INDICATION, 2015 TO 2023 (USD MILLION)

TABLE 126 AFRICA BIOLOGICS MARKET BY MANUFACTURING, 2015 TO 2023 (USD MILLION)

"Single User License: OnIine PDF View Only
Enterprise-user License : Print & download option is available."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Novartis AG (Switzerland), F. Hoffman-La Roche AG (Switzerland), AbbVie, Inc. (U.S.), Pfizer Inc. (U.S.), AstraZeneca (U.K.), Bayer AG (Germany), Amgen (U.S.), GlaxoSmithKline Plc (U.K.), Sanofi (France), Eli Lilly and Company (U.S.)